WSTAM
AKCA

Wilbanks Smith & Thomas Asset Management’s Akcea Therapeutics Inc AKCA Stock Holding History

Wilbanks Smith & Thomas Asset Management’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-40
Closed -$1K – 1482
2018
Q3 		$1K Buy
+40
New +$1.21K ﹤0.01% 1590

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wilbanks Smith & Thomas Asset Management's AKCA Position: Q4 2018 in Review

Wilbanks Smith & Thomas Asset Management sold out of Akcea Therapeutics Inc (AKCA) in Q4 2018, closing a stake of 40 shares — an estimated $1K sold.

Wilbanks Smith & Thomas Asset Management first reported a position in AKCA in Q3 2018 and held it in 1 quarter. The position peaked at $1K in Q3 2018. 62 funds tracked by Wall St. Rank hold AKCA as of Q4 2018.

  • Wilbanks Smith & Thomas Asset Management reported no remaining Akcea Therapeutics Inc position as of Q4 2018 after selling out during the quarter.
  • Wilbanks Smith & Thomas Asset Management sold 40 Akcea Therapeutics Inc shares in Q4 2018, an estimated $1K.
  • Wilbanks Smith & Thomas Asset Management first reported a position in Akcea Therapeutics Inc in Q3 2018 and held it in 1 quarter.
  • Wilbanks Smith & Thomas Asset Management's Akcea Therapeutics Inc position peaked at $1K in Q3 2018.
  • 62 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2018.

Based on Wilbanks Smith & Thomas Asset Management's 13F filing for Q4 2018, filed 8 Feb 2019.